ADMA Biologics auditor CohnReznick resigning effective after Q3 2024 filing; audit committee seeking replacement

ADMA BIOLOGICS, INC.

CohnReznick LLP notified ADMA of resignation as independent auditor effective after filing of Q3 2024 10-Q.
No disagreements or reportable events during fiscal years 2022 and 2023 or subsequent interim period.
Audit Committee initiated process to select new auditor for FY 2024 audit and internal control over financial reporting.
CohnReznick's reports on FY 2023 and 2022 financials were unqualified, no adverse opinion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.